Loading stock…

Tarsus Pharmaceuticals, Inc. (TARS) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Tarsus Pharmaceuticals, Inc.

TARSMarket cap $3.25BPrice $74.1

Country🇺🇸United States

SectorHealthcare

IndustryPharmaceuticals

Develops treatments for eye and skin conditions caused by tiny mites most people don't know exist. Its flagship drug became the first FDA-approved treatment for Demodex blepharitis, a condition affecting 25 million Americans, unlocking a market nobody else had touched.

In Bastion Portfolios?

52W Return+2%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+160%10

Revenue Forecast

Rev CAGR (1y)+60%10

Rev CAGR (3y)+37%10

Rev CAGR (5y)+34%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+30%5

Quality

Margins

EBIT Margin-8%1

Net Income Margin-8%1

Free Cash Flow Margin9%6

Debt

Net Debt/EBITDAna–

Efficiency

ROE-14%1

ROA-8%1

Earnings Stabilityna–

GEAR+WEAK32

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)126

P/BV9.42

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield1.7%4

Dividend Yieldna–

Momentum

Short term

1 month return-18%1

3 month return+5%8

YTD return-9%3

Mid term

Price vs 52wHigh81%5

1 year return+8%6

Long term

3 year return+322%10

5 year return+235%9

Risk Shield

Price Risk

Beta0.29

Volatility45%4

Free Cash Flow

Free Cash Flow Margin9%6

Free Cash Flow Yield1.7%4

Quality

ROCE-12%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

TARSTarsus Pharmaceuticals

Revenue FY25$451M

GROWTH RATING↗

VERY STRONG92 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+160%10

Revenue, next 1Y+60%10

Revenue, next 3Y, CAGR+37%10

Revenue, next 5Y, CAGR+34%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28E0%5

GROWTH ASSESSMENT

STRENGTHS

It out-grows 92% of companies worldwide.

Revenue grew 160%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 37%/yr over the next 3 years, ahead of most of the market.10/10

The runway holds up: revenue is set to grow 34%/yr over five years.10/10

WATCH

Revenue grew 160%/yr over the last 3 years; forecasts see it cooling to 37%/yr.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE65 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-18%1

3-month return+5%8

YTD return-9%3

MID & LONG-TERM▾SCORE

% of 52-week high81%5

1-year return+8%6

3-year return+322%10

5-year return+235%9

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +322% over three years and +235% over five, ahead of 90% of the market.

Strong recent results. The stock is outperforming over three months (+5%).

WATCH

It's up 8% over the past year, but 19% below its 52-week high. That is a touch ahead of the market.

WEAKNESSES

The stock is underperforming over the past month (-18%) and so far this year (-9%).

BOTTOM LINE

Long-Term Winner, Cooling Off

Multi-year returns are elite even though the latest weeks are quieter. Often a quality compounder taking a breather rather than breaking down. The one thing to watch: the stock is underperforming over the past month and so far this year.

04Value

Are you paying a fair price for it?

Stop guessing on Tarsus Pharmaceuticals, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

TARSTarsus Pharmaceuticals

Revenue FY25$451M

GROWTH RATING↗

VERY STRONG92 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+160%10

Revenue, next 1Y+60%10

Revenue, next 3Y, CAGR+37%10

Revenue, next 5Y, CAGR+34%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27ELoss1

EPS growth, FY28E0%5

GROWTH ASSESSMENT

STRENGTHS

It out-grows 92% of companies worldwide.

Revenue grew 160%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 37%/yr over the next 3 years, ahead of most of the market.10/10

The runway holds up: revenue is set to grow 34%/yr over five years.10/10

WATCH

Revenue grew 160%/yr over the last 3 years; forecasts see it cooling to 37%/yr.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE65 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-18%1

3-month return+5%8

YTD return-9%3

MID & LONG-TERM▾SCORE

% of 52-week high81%5

1-year return+8%6

3-year return+322%10

5-year return+235%9

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +322% over three years and +235% over five, ahead of 90% of the market.

Strong recent results. The stock is outperforming over three months (+5%).

WATCH

It's up 8% over the past year, but 19% below its 52-week high. That is a touch ahead of the market.

WEAKNESSES

The stock is underperforming over the past month (-18%) and so far this year (-9%).

BOTTOM LINE

Long-Term Winner, Cooling Off

04Value

Are you paying a fair price for it?

Stop guessing on Tarsus Pharmaceuticals, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community